AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05682339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of quinine and L-isoleucine
Description: In this condition, both quinine and L-isoleucine will be administered as 'active'.
Study NCT05682339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In the condition, where quinine is 'active', control for L-isoleucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-isoleucine will be 'active', control for quinine (10 ml distilled water) will be administered.~Whereas, in a control condition, both for quinine and L-isoleucine, a control solution will be administered.
Study NCT05682339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: In the condition, where quinine is 'active', control for L-isoleucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-isoleucine will be 'active', control for quinine (10 ml distilled water) will be administered.~Whereas, in a control condition, both for quinine and L-isoleucine, a control solution will be administered.
Study NCT04934566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECMO flow
Description: Dynamic changes in ECMO flow and SvO2 measurement at the 3 different sites.
Study NCT05737472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-protein RUTF
Description: The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
Study NCT05737472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard RUTF
Description: The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.
Study NCT05594862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lipogems
Description: Micro-fragmented adipose tissue infiltration
Study NCT04763499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: freeze dried strawberry powder
Description: approximately 24 strawberries that have been freeze dried into a powder
Study NCT04763499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: freeze dried strawberry powder
Description: approximately 24 strawberries that have been freeze dried into a powder
Study NCT04777890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suboccipital inhibition
Description: The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
Study NCT05679570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab (Genetical Recombination)
Description: Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period\[1\]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period\[2\]:~Subjects completed continuation dosing period\[1\], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period.
Study NCT04777890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INYBI
Description: The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
Study NCT04777890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INYBI + upper cervical manipulation
Description: The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
Study NCT06355869 — intervention group
Intervention type: OTHER
Intervention: repeated 3D gait-analysis
Description: An observational 3D gait-analysis was performed with a period of 1-14 days is foreseen between the two measurements.
Study NCT05526872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care
Study NCT05526872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT05526872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Receive educational materials
Study NCT05526872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT05526872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study NCT05526872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Planned Notification
Description: Receive planned reminders to schedule mammogram
Study NCT05526872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05526872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04908254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crossover Device (PCD or Dayspring - alternate to first group)
Description: Cross over arms after a month of use and a month of washout period
Study NCT04908254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover Device (PCD or Dayspring - alternate to first group)
Description: Cross over arms after a month of use and a month of washout period
Study NCT05255458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT05255458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT06205940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audioguided Nature tour
Description: Listening to audio instructions by an app while visiting nature. The instructions emphasize the connection between self and nature and direct attention to the present moment experience by guiding focus towards sensory experiences and specific natural elements.
Study NCT06205940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non audio guided nature tour
Description: Visiting nature without listening to audio instructions by an app
Study NCT06397001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nL-SAA1-01
Description: Personalized antisense oligonucleotide
Study NCT05258136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose CD20 monoclonal antibody injection
Description: To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
Study NCT05622604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pray.com app (autonomous use)
Description: Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
Study NCT05622604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pray.com app (meditative prayer condition)
Description: Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
Study NCT05184192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin gelatin capsules 300mg
Description: Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
Study NCT05184192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose monohydrate NF
Study NCT06345547 — intervention group
Intervention type: OTHER
Intervention: ultrasound
Description: Ultrasound of m. quadriceps and m. thenar All ultrasound measurements will be performed in triplicate, with the average of the scores used in final analyses. Four parameters will be evaluated: muscle thickness, muscle cross sectional area, pennation angle and echo intensity (gain, depth and frequency will be kept constant).~Hand grip strength measurement: measurement by an electronic hand dynamometer DynEx1TM (MD Systems, Inc. Ohio, USA). The recommendations for the handgrip strength test of the American Society of Hand Therapists will be followed: The maximum of the three values will be considered for analysis.
Study NCT04733950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)
Description: Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target.
Study NCT04733950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)
Description: Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target.
Study NCT04733950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of the pupil diameter for the evaluation of listening effort during speech perception
Description: Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
Study NCT05101057 — intervention group
Intervention type: DEVICE
Intervention: SpinalogicTM Bone Graft Stimulator
Description: The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.
Study NCT05237674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The TEACHOUT intervention
Description: The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings.
Study NCT05992207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor imaginary training
Description: Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi#reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
Study NCT05992207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy training
Description: facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
Study NCT04733950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of the pupil diameter for the evaluation of listening effort during speech perception
Description: Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
Study NCT06539078 — intervention group
Intervention type: OTHER
Intervention: Maximal exercise test
Description: Participants will undertake an incremental ramp test on a cycle ergometer to determine maximal oxygen uptake (V̇O2max) and the gas exchange threshold (GET). Throughout the exercise test, muscle oxygenation and deoxygenation will be monitored by NIRS.
Study NCT06279455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise
Description: A 12-week pelvic floor muscle exercise program was applied to pregnant women.
Study NCT05120414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balanace exercises
Description: Balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
Study NCT05120414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Exercises plus Ankle strategy
Description: ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.While balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
Study NCT02777762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun First
Description: 8 weekly interactive small-group sessions with a health coach
Study NCT02777762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Close at Hand
Description: 8 weekly check-ins with a state of the art, engaging mobile app
Study NCT06539078 — intervention group
Intervention type: OTHER
Intervention: 3D Ultrasound
Description: Muscle volume and morphological characteristics will be assessed via 3D ultrasound imaging.
Study NCT06539078 — intervention group
Intervention type: OTHER
Intervention: Dynamometry
Description: To determine the contractile properties of the knee extensors, participants will perform maximal isometric and isoinertial contractions of the knee extensors on a dynamometer.
Study NCT06539078 — intervention group
Intervention type: OTHER
Intervention: Exercise test and occlusions
Description: Participants will perform a series of moderate-intensity constant power output exercise bouts on a cycle ergometer following which the recovery rates of muscle V̇O2 will be determined via a series of intermittent arterial occlusions. Throughout all tests, pulmonary gas exchange and ventilation will be determined and muscle oxygenation and deoxygenation will be monitored by NIRS.
Study NCT06539078 — intervention group
Intervention type: OTHER
Intervention: Exercise test in MRI
Description: Exercise will be performed on a custom-built magnetic resonance-compatible cycle ergometer in supine position for determination of muscle phosphocreatine recovery kinetics using 31phosphorous magnetic resonance spectroscopy \[31P-MRS\].
Study NCT06539078 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: A muscle biopsy will be obtained from the vastus lateralis using a modified Bergström needle technique with suction.
Study NCT05384119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral tablet
Study NCT05384119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Oral capsule
Study NCT05384119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI)
Description: Oral tablet
Study NCT04775563 — intervention group
Intervention type: OTHER
Intervention: COVID-19 vaccine hesitancy scale in rheumatic diseases
Description: The instrument was developed by Freeman et al, prior to its application, translation, cultural adaptation, and validation were performed.
Study NCT04775563 — intervention group
Intervention type: OTHER
Intervention: COVID-19 vaccine hesitancy associated factors
Description: The instrument includes questions about the doctor-patient relationship, perception of the COVID-19 vaccine, perception of risk of COVID-19 infection, perception of the severity of the pandemic in Mexico, perception of the severity of their rheumatic disease, perception of the control of comorbidities, perception of the intensity of the immunosuppressive treatment, positioning of the patient towards vaccines for COVID-19
Study NCT05487963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib Citrate
Description: Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
Study NCT05487963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo ointment
Description: Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
Study NCT05137392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oral hygiene instruction
Description: The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.
Study NCT05137392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral hygiene instruction
Description: The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.
Study NCT05359744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Performance testing
Description: Performance testing on a bicycle ergometer.
Study NCT04550624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: 200mg IV on day 1 of each cycle
Study NCT04899674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elontril
Description: Elontril
Study NCT04550624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: 20mg PO daily days 1-21 of each cycle
Study NCT05497089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temelimab 54mg/kg
Description: Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
Study NCT05497089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
Study NCT05029141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAHAG regimen
Description: Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC > 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.
Study NCT05384119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Oral tablet